Eton Pharmaceuticals beats Q4 adjusted EPS estimates

Eton Pharmaceuticals

19/03/2026 20:29

Overview

U.S. rare disease drugmaker's Q4 product sales rose 83% yr/yr, driven by new launches

Adjusted EPS for Q4 beat analyst expectations

Company launched DESMODA and acquired U.S. rights to HEMANGEOL, both expected to drive growth

Outlook

Eton expects 2026 revenue to exceed $110 mln

Company sees 2026 Adjusted EBITDA margin of at least 30%

Company expects DESMODA and HEMANGEOL to be key growth contributors in 2026

Result Drivers

NEW PRODUCT LAUNCHES - Q4 sales growth driven by addition of INCRELEX, GALZIN, and KHINDIVI, as well as strong growth in ALKINDI SPRINKLE

 R&D expenses for the fourth quarter of 2025 were $1.8 million compared to loss of $0.9 million in the prior year period

Company press release: ID:nGNX1ldZw4

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
Beat
$0.19
$0.09 (3 Analysts)
Q4 EPS
$0.05
Q4 Net Income
$1.48 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Eton Pharmaceuticals Inc is $30.00, about 57.7% above its March 18 closing price of $19.02

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 15 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)